CBMG_CTIL051 (Non-Small Cell Lung Cancer) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if the combination of 2 experimental drugs called C-TIL051 and NKTR-255 when they are given along with pembrolizumab is a safe and effective option for non-small cell lung cancer (NSCLC). C-TIL051 is custom-made for each participant from their own tumor tissue. Immune cells are isolated from your tumor tissue, regrown in a lab, and then formulated to be returned to your bloodstream. We want to know if C-TIL051 can help people's immune systems target and destroy cancer cells. NKTR-255 is designed to help C-TIL051 work better.
Non-Small Cell Lung Cancer (NSCLC)
Who Can Participate in the Study?
Adults ages 18 or older who:
- Are diagnosed with NSCLC
- Have not received checkpoint inhibitor therapy
- Have tumor tissue that can be surgically removed
- Have never received treatment with a cellular therapy
For more information about who can join this study, please contact the study team at 919-681-6468.
What is Involved?
If you choose to join this study, you will:
- Undergo surgery to collect your tumor tissue to make the study drug
- Receive lympho-depleting chemotherapy
- Take the study drugs
- Have physical exams and blood draws
- Have imaging scans (CT and/or MRI)
- Have heart tests (ECG)
Study Details
